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Letters to the Editor
59Adrenal insufﬁciency: Diagnosis in patients with liver cirrhosis
is difﬁcultReply to Montagnese et al.:
We were very interested by the letter of Montagnese et al. pub-
lished in this issue of the Journal of Hepatology [1]. Many recent
publications led us to believe that adrenal insufﬁciency, assessed
by serum total cortisol assays, was very common in patients with
liver cirrhosis [2–7]. In fact, cortisol transport proteins (cortisol
binding globulin and albumin) are often decreased in patients
with cirrhosis, leading to a reduced bound fraction of cortisol,
whereas free cortisol concentration, which is the active fraction
of cortisol, remains unchanged. We recently showed that serum
total cortisol assays (performed at 8 AM before and after a corti-
cotropin injection) largely overestimate adrenal insufﬁciency
prevalence in patients with cirrhosis, especially in those with
serum albumin 625 g/L [8].
Interestingly, Montagnese and colleagues assessed the 24-h
rhythm of cortisol in patients with cirrhosis using plasma free
cortisol assays, avoiding the bias of the reduced cortisol transport
proteins. They report that patients with Child-Pugh B/C cirrhosis
have signiﬁcantly lower plasma free cortisol concentrations and
that their rhythm onset and offset are (not signiﬁcantly) delayed
compared to patients with Child-Pugh A cirrhosis. This delay
could make the diagnosis of adrenal insufﬁciency more compli-
cated in patients with severe cirrhosis.
In our study, we found that adrenal insufﬁciency assessed by
salivary cortisol (an accurate reﬂection of free cortisol) was lower
than previously reportedwith serum total cortisol, but not rare (8/
88: 9.1%) [8]. All eight patients with adrenal insufﬁciency were
classiﬁed as Child-Pugh C. It is unlikely that our results are partly
explained by the delayed cortisol rhythm of patients with Child-
Pugh B/C cirrhosis highlighted by Montagnese and colleagues. In
fact, the maximal plasma free cortisol concentration seems very
close to 8 AM in the study of Montagnese, which is the moment
whenwe collected saliva and blood samples to assess cortisol con-0 Journal of Hepatology 20centrations. These interesting results should be conﬁrmed by a
larger study (Montagnese and colleagues included 4 patients with
Child-Pugh B and two patients with Child-Pugh C) to determine if
this delay has reliable consequences on the diagnosis of adrenal
insufﬁciency in patients with cirrhosis.
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To the Editor:
We read with great interest the letter by Neumann et al. [1] on
the effect of Silibinin in preventing graft infection in a patient
with cirrhosis due to chronic hepatitis C (HCV). We obtained
the same result in a patient treated with intravenous (i.v.) Silibi-
nin mono-therapy (Legalon SIL, Rottapharm-Madaus).
In 1994, the 46-year-old male patient with beta-thalassemia
was ﬁrst diagnosed for HCV with mixed genotype 1a/4. Both
genotypes were also present upon starting silibinin treatment
and on the day of OLTx. In 1998, he was treated with 5 MU inter-
feron three times a week and weight based ribavirin. Treatment
was stopped due to failure to clear the virus after 24 weeks of
treatment.
In 2009, he presented with end stage liver failure (Child–Pugh
stage C, MELD 20). In the mean time, he had developed insulin
dependent diabetes mellitus which is treated with insulin aspar-
tate (Novomix 30 100 E/ml, Novo Nordisk Pharma GmbH; 16 IE-
0-0/day). He was listed for orthotopic liver transplantation (OLT)
on the 29th of October 2009. Based on our observation of the
potent antiviral effects of Silibinin [2,3] a feasibility study was
discussed in the transplant setting.
Accordingly, a patient placed ﬁrst on the waiting list for OLT
should receive i.v. Silibinin. In this patient a donor liver became
available on day 15 of Silibinin mono-therapy. The data on virus
concentrations, obtained pre and after OLT, are shown in Fig. 1.
Baseline virus load was low (28.800 IU/ml) and decreased on
intravenous Silibinin mono-therapy to 43 IU/ml on the day of
OLTx. Due to a miscommunication between our outpatient center
and the OLT-team, treatment was interrupted for 2 days after OLT
and virus concentration increased to 115 IU/ml. Nevertheless,
HCV-RNA levels decreased after resuming Silibinin-infusions to
30 IU/ml on day 6 and became unquantiﬁable (<15 IU/ml) on
day 10, and undetectable on day 22 after OLT. Silibinin was
stopped 25 days after OLT. During 5 months of follow-up, HCV-
RNA levels remained undetectable.
The surgical procedure and post-operative phase went ahead
without any complications. Immunosuppressive therapy
included prednisolone and cyclosporine A. Like in the patient of
Neumann et al. [1] bilirubin levels increased during treatment
with Silibinin to a maximum of 17.15 mg/dl (on day 3 post
OLT) but decreased continuously while the patient was still on
Silibinin. The higher increase of bilirubin in our patient could
be due to the longer administration of Silibinin combined with
the post-operative phase. Aminotransferase levels reached nearly
normal values (ASAT 39 U/l, ALAT 32 U/l) 4 days after starting Sil-
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ibinin-infusions but increased again after OLT and reached nor-
mal levels within 4 weeks after OLT.
While the goal to prevent graft infection was reached in both
patients, the approaches were different. Neumann et al. [1]
started Silibinin application 8 h after the anhepatic phase (while
the viral load was 182 IU/ml). Our patient was pretreated with
Silibinin for 15 days with an interruption of 2 days in the post-
operative period. Previously, we have shown in a non-responders
cohort that the interruption of Silibinin treatment over the week-
end results in an increase in viral load [4]. The doses of Silibinin
were slightly different. While Neumann et al. used a ﬁxed dose
of 1400 mg/day we applied 20 mg/kg body weight/day. The low
baseline viral load may be a condition favoring the action of
Silibinin.
These encouraging observations should lead to a prospective
evaluation of i.v. Silibinin in this group of patients, having no
medical alternatives to prevent graft infection. Studies are
needed to ﬁnd the best way to apply this concept in future (tim-
ing, duration, and optimal dose).
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Fig. 1. HCV-kinetics during silibinin i.v. monotherapy. HCV RNA levels
measured by real-time PCR (Cobas Taqman, Roche Diagnostics, Pleasanton, CA).
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